Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cytarabine
Drug ID BADD_D00560
Description A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indications and Usage For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Marketing Status Prescription; Discontinued
ATC Code L01BC01
DrugBank ID DB00987
KEGG ID D00168
MeSH ID D003561
PubChem ID 6253
TTD Drug ID D07XSN
NDC Product Code 67457-452; 68083-343; 58623-0026; 68083-337; 67457-455; 71288-108; 61703-303; 70516-0163; 71288-109; 61703-319; 63323-120; 71288-169; 61703-305; 71288-168; 55512-0026; 61703-304; 12848-1003
Synonyms Cytarabine | Arabinosylcytosine | Cytosine Arabinoside | Arabinoside, Cytosine | Arabinofuranosylcytosine | Aracytidine | beta-Ara C | beta Ara C | Cytarabine Hydrochloride | Cytosar | Cytosar-U | Cytosar U | Ara-C | Ara C | Aracytine | Cytonal
Chemical Information
Molecular Formula C9H13N3O5
CAS Registry Number 147-94-4
SMILES C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Brain injury19.07.03.007; 17.11.01.0030.000139%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.001598%
Acute kidney injury20.01.03.0160.010923%
Traumatic lung injury22.01.02.013; 12.01.03.0030.001598%Not Available
H1N1 influenza11.05.03.002; 22.07.02.0070.000533%Not Available
Foetal growth restriction18.03.01.0020.000533%
Posterior reversible encephalopathy syndrome17.13.02.0070.002398%
Central nervous system haemorrhage24.07.04.016; 17.08.01.0350.000347%Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.001865%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Candida infection11.03.03.0210.003730%
Aspergillus infection11.03.01.0040.000973%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.002085%
Culture urine positive13.08.02.0070.001066%Not Available
Ecthyma23.07.03.015; 11.01.12.0220.000799%Not Available
Jugular vein thrombosis24.01.02.0070.001066%Not Available
PCO2 increased13.02.01.0300.000533%Not Available
Pneumonia pseudomonal22.07.06.014; 11.02.12.0040.000208%Not Available
Intracranial hypotension17.02.05.036; 12.01.10.0080.000533%Not Available
Fusarium infection11.03.05.0220.000486%Not Available
Stenotrophomonas infection11.02.01.0490.000278%Not Available
Enterococcal sepsis11.02.08.0050.000139%Not Available
Clostridium difficile infection11.02.02.0090.000533%Not Available
Multi-organ disorder08.01.03.0740.000208%Not Available
Sinusitis fungal22.07.03.029; 11.03.05.0300.000533%Not Available
Bone marrow necrosis24.04.09.002; 01.05.01.0120.000533%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.000278%Not Available
Bacillus infection11.02.22.0030.000208%Not Available
Escherichia infection11.02.10.0040.001066%Not Available
Klebsiella infection11.02.03.0030.000799%Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages